Abnormal ECG in Lymphoma: Should You Be Concerned?

Many people with lymphoma have ECG (electrocardiogram) changes during diagnosis or treatment, and these are often mild and do not cause symptoms. In clinical experience with common cancer medicines like paclitaxel, about 23% of patients show ECG changes, and most require no intervention. ^[1] Even those who start with a normal ECG can develop an abnormal tracing, and these changes are usually non‑specific and not dose‑limiting. ^[1]

---

Why ECG Changes Happen

• Cancer therapies (chemotherapy/targeted drugs): Several lymphoma treatments can affect heart rhythm or the heart’s electrical intervals (like QTc). Agents such as paclitaxel are known to cause ECG changes, typically non‑specific and not dangerous in most cases. ^[2] Guidance documents list multiple anti‑cancer agents that may prolong QTc or cause arrhythmias, prompting routine ECG monitoring. ^[3]

• Baseline cardiovascular risk: It’s common to find ECG abnormalities at baseline in people with cancer, reflecting age, prior heart disease, or electrolyte issues, not necessarily the cancer itself. ^[1] These background changes often remain stable and asymptomatic during treatment. ^[1]

• Cardiac involvement from lymphoma (rare): In some cases, lymphoma can involve the heart or pericardium, which may alter ECGs; with careful management, even patients with cardiac involvement have been treated safely (for example, with CAR‑T). ^[4] A coordinated cardio‑oncology approach helps balance cancer control with heart safety. ^[5]

---

Common Types of ECG Abnormalities

• Non‑specific ST‑T changes: Frequently reported and often benign during therapy like paclitaxel. ^[1]
• QTc prolongation: Seen with several anti‑cancer drugs; warrants electrolyte checks and periodic ECGs. ^[3]
• Bradycardia or conduction block: Described with certain targeted agents; usually monitored and managed conservatively unless symptomatic. ^[2]

---

When To Be More Watchful

Most ECG changes in lymphoma care are not dangerous, but some patterns need closer attention:

• New chest pain, shortness of breath, fainting, palpitations, or severe dizziness: These symptoms, together with ECG changes, can signal ischemia or arrhythmias and should be assessed promptly. ^[6]
• Marked QTc prolongation (for example >480–500 ms): Treatment may be paused, electrolytes corrected, and ECGs repeated until QTc improves. ^[7] Dose adjustments or discontinuation are considered if QTc is severely prolonged or associated with dangerous rhythms like torsades de pointes. ^[8]

---

How Clinicians Usually Manage ECG Changes

• Routine monitoring: ECG at baseline and during treatment, especially in the first weeks after starting a drug known to prolong QTc or affect rhythm; electrolytes (potassium, magnesium, calcium) are checked and corrected when needed. ^[9] Additional ECGs are obtained as clinically indicated or after adding medicines that can affect QTc. ^[10]

• Risk reduction: Keeping electrolytes in the normal range lowers arrhythmia risk, and avoiding combinations of QT‑prolonging drugs helps reduce problems. ^[3] Patients with pre‑existing heart disease are monitored more closely, sometimes with echocardiograms to assess heart function. ^[11]

• Treatment adjustments: If significant ECG changes occur, clinicians may hold the cancer drug, reduce the dose, or switch therapies, balancing heart safety with cancer control. ^[8] This is individualized and guided by how severe the ECG change is and whether symptoms are present. ^[7]

---

Practical Tips For You

• Ask what your ECG change means: “Non‑specific” changes often have no symptoms and may not alter your treatment plan. ^[1]
• Share symptoms promptly: Report chest pain, palpitations, fainting, or new shortness of breath. ^[6]
• Keep electrolytes safe: Follow guidance on hydration and nutrition; your team may check and correct potassium and magnesium before and during therapy. ^[9]
• Know your medicines: Some anti‑cancer and non‑cancer drugs can both prolong QTc; your team will coordinate to minimize overlaps and monitor accordingly. ^[3]
• Cardio‑oncology support: Many centers use a cardio‑oncology approach to safely continue effective cancer therapy while protecting the heart. ^[5]

---

Bottom Line

An “abnormal ECG” in lymphoma care often reflects common, mild changes that don’t cause symptoms and usually don’t require stopping treatment. ^[1] Your care team watches for the few patterns that matter significant QTc prolongation, ischemic changes, or symptomatic arrhythmias and has clear steps to manage them safely. ^[7] With routine monitoring and attention to symptoms, most people continue lymphoma therapy without serious heart issues. ^[9]